EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stride Velocity 95 th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy

Michael Rabbia, Maitea Guridi Ormazabal, Hannah Staunton, Klaas Veenstra, Damien Eggenspieler, Mélanie Annoussamy, Laurent Servais, Paul Strijbos

Journal of Neuromuscular Diseases · 2024

DOI: 10.3233/jnd-230188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2024. Verfasst von Michael Rabbia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genentech Inc., 1 DNA Way, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Walk Test, Walking. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stride Velocity 95 th Centile (SV95C) is the first wearable device-derived clinical outcome assessment (COA) to receive European Medicines Agency (EMA) qualification as a primary endpoint in ambulant patients with Duchenne muscular dystrophy (DMD) aged ≥4 years.

Objective

To compare SV95C—in its first-ever clinical trial application as a secondary endpoint—with established motor function COAs used in the trial (Four-Stair Climb [4SC] velocity, North Star Ambulatory Assessment [NSAA], and Six-Minute Walk Distance [6MWD]).

Methods

SV95C was a secondary endpoint in a subset ( n = 47) of participants in the SPITFIRE/WN40227 trial of taldefgrobep alfa, which was discontinued due to lack of clinical benefit. Participants in the ≤48-week SV95C sub-study were 6–11 years old and received corticosteroids for ≥6 months pre-treatment. Pearson correlations were used to compare SV95C with the other COAs. Responsiveness and changes over time were respectively assessed via standardized response means (SRMs) based on absolute changes and mixed models for repeated measures.

Results

SV95C change at Week 24 was –0.07 m/s, with limited variability (standard deviation: 0.16, n = 27). The SRM for SV95C indicated moderate responsiveness to clinical change at the earliest timepoint (Week 12, n = 46), while those of the other COAs did not indicate moderate responsiveness until Week 36 (6MWD, n = 33) or Week 48 (4SC velocity, n = 20; NSAA total score, n = 20). Baseline correlations between SV95C and other COAs were strong ( r = 0.611–0.695). Correlations between SV95C change from baseline to Week 48 and changes in other COAs were moderate to strong ( r = 0.443–0.678).∥ Conclusions: Overall, SV95C demonstrated sensitivity to ambulatory decline over short intervals, low variability, and correlation with established COAs. Although the negative trial precluded demonstration of SV95C’s sensitivity to drug effect, these findings support the continued use of SV95C in DMD clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneWalk TestWalkingHumansChildMaleOutcome Assessment, Health CareWearable Electronic DevicesFemale

Stichwörter der Autor:innen

ambulationclinical trialsdigital endpointsdystrophymuscularstride velocity 95th centile

Autor:innen und Institutionen

  • Genentech Inc., 1 DNA Way, South San Francisco, CA, USA.
  • F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland.
  • Roche Products Ltd, Hexagon Place, Shire Park, 6 Falcon Way, Welwyn Garden City, UK.
  • SYSNAV, 72 Rue Emile Loubet, Vernon, France.
  • MDUK Oxford Neuromuscular Centre and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Department of Pediatrics, Division of Child Neurology, Centre de Référence des Maladies Neuromusculaires, University Hospital Liège and University of Liège, Avenue de l'Hôpital 1, Liege, Belgium.

Zitieren

APA

Rabbia, M., Guridi Ormazabal, M., Staunton, H., Veenstra, K., Eggenspieler, D., Annoussamy, M., Servais, L., & Strijbos, P. (2024). Stride Velocity 95 th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-230188

Vancouver

Rabbia M, Guridi Ormazabal M, Staunton H, Veenstra K, Eggenspieler D, Annoussamy M, et al. Stride Velocity 95 th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 2024. doi:10.3233/jnd-230188

BibTeX
@article{Rabbia2024,
  author = {Rabbia, Michael and Guridi Ormazabal, Maitea and Staunton, Hannah and Veenstra, Klaas and Eggenspieler, Damien and Annoussamy, Mélanie and Servais, Laurent and Strijbos, Paul},
  title = {Stride Velocity 95 th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy},
  journal = {Journal of Neuromuscular Diseases},
  year = {2024},
  doi = {10.3233/jnd-230188}
}
Kostenlos starten →